Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology
Market Cap
$6.61 Million
AU$10.68 Million AUD
Market Cap Rank
#33812 Global
#1196 in Australia
Share Price
AU$0.04
Change (1 day)
-16.67%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.34
Categories
Companies in Australia Biotechnology
About

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more

Bio-Gene Technology Ltd (BGT) - Net Assets

Latest net assets as of December 2025: AU$1.17 Million AUD

Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has net assets worth AU$1.17 Million AUD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.47 Million) and total liabilities (AU$307.71K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$1.17 Million
% of Total Assets 79.13%
Annual Growth Rate 16.97%
5-Year Change -61.68%
10-Year Change 243.72%
Growth Volatility 547.88

Bio-Gene Technology Ltd - Net Assets Trend (2014–2025)

This chart illustrates how Bio-Gene Technology Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Bio-Gene Technology Ltd (2014–2025)

The table below shows the annual net assets of Bio-Gene Technology Ltd from 2014 to 2025.

Year Net Assets Change
2025-06-30 AU$1.63 Million -41.71%
2024-06-30 AU$2.79 Million -13.35%
2023-06-30 AU$3.22 Million -48.61%
2022-06-30 AU$6.27 Million +47.63%
2021-06-30 AU$4.25 Million -29.26%
2020-06-30 AU$6.00 Million +21.27%
2019-06-30 AU$4.95 Million -28.34%
2018-06-30 AU$6.91 Million -23.86%
2017-06-30 AU$9.07 Million +1816.45%
2016-06-30 AU$473.35K +63.21%
2014-06-30 AU$290.03K --

Equity Component Analysis

This analysis shows how different components contribute to Bio-Gene Technology Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2105456200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$22.94 Million 1410.24%
Other Comprehensive Income AU$712.09K 43.77%
Total Equity AU$1.63 Million 100.00%

Bio-Gene Technology Ltd Competitors by Market Cap

The table below lists competitors of Bio-Gene Technology Ltd ranked by their market capitalization.

Company Market Cap
Wedgemount Resources Corp.
OTCQB:WDGRF
 		$2.33 Million
Arax Holdings Corp
PINK:ARAT
 		$2.33 Million
Sycal Ventures Bhd
KLSE:9717
 		$2.33 Million
Eniro Group AB
LSE:0YG8
 		$2.33 Million
F5 NETWORKS - Dusseldorf Stock Exchang
DU:FFV
 		$2.33 Million
IPHSF
OTCGREY:IPHSF
 		$2.33 Million
China Ouhua Winery Holdings
KLSE:5188
 		$2.33 Million
Z.M.H Hammerman Ltd
TA:ZMH
 		$2.33 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bio-Gene Technology Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,791,144 to 1,627,016, a change of -1,164,128 (-41.7%).
  • Net loss of 2,584,468 reduced equity.
  • Share repurchases of 75,989 reduced equity.
  • New share issuances of 1,496,328 increased equity.
  • Other comprehensive income decreased equity by 194,946.
  • Other factors increased equity by 194,947.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-2.58 Million -158.85%
Share Repurchases AU$75.99K -4.67%
Share Issuances AU$1.50 Million +91.97%
Other Comprehensive Income AU$-194.95K -11.98%
Other Changes AU$194.95K +11.98%
Total Change AU$- -41.71%

Book Value vs Market Value Analysis

This analysis compares Bio-Gene Technology Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.54x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 8.79x to 4.54x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-06-30 AU$0.00 AU$0.04 x
2015-06-30 AU$0.00 AU$0.04 x
2016-06-30 AU$0.00 AU$0.04 x
2017-06-30 AU$0.07 AU$0.04 x
2018-06-30 AU$0.06 AU$0.04 x
2019-06-30 AU$0.04 AU$0.04 x
2020-06-30 AU$0.05 AU$0.04 x
2021-06-30 AU$0.03 AU$0.04 x
2022-06-30 AU$0.04 AU$0.04 x
2023-06-30 AU$0.02 AU$0.04 x
2024-06-30 AU$0.02 AU$0.04 x
2025-06-30 AU$0.01 AU$0.04 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bio-Gene Technology Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -158.85%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -608.01%
  • • Asset Turnover: 0.20x
  • • Equity Multiplier: 1.32x
  • Recent ROE (-158.85%) is below the historical average (-57.39%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -30.10% -114876.32% 0.00x 1.00x AU$-116.31K
2015 -22.57% -9826.10% 0.00x 1.00x AU$-141.80K
2016 -68.14% -173.01% 0.22x 1.81x AU$-369.85K
2017 -11.63% -16702.06% 0.00x 1.04x AU$-1.96 Million
2018 -41.02% -822.49% 0.04x 1.11x AU$-3.52 Million
2019 -38.79% -377.34% 0.09x 1.12x AU$-2.41 Million
2020 -32.21% -212.99% 0.14x 1.09x AU$-2.53 Million
2021 -56.43% -3827.29% 0.01x 1.18x AU$-2.82 Million
2022 -46.49% -653.81% 0.06x 1.17x AU$-3.54 Million
2023 -96.10% -2074.48% 0.04x 1.19x AU$-3.42 Million
2024 -86.32% -13150.54% 0.01x 1.13x AU$-2.69 Million
2025 -158.85% -608.01% 0.20x 1.32x AU$-2.75 Million

Industry Comparison

This section compares Bio-Gene Technology Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $34,878,957
  • Average return on equity (ROE) among peers: -61.33%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Bio-Gene Technology Ltd (BGT) AU$1.17 Million -30.10% 0.26x $2.33 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million